Credit Suisse Group reiterated their buy rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a report published on Monday morning. They currently have a $485.00 target price on the biopharmaceutical company’s stock.

Several other research analysts have also issued reports on the stock. Zacks Investment Research lowered shares of Regeneron Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Tuesday, July 4th. Vetr lowered shares of Regeneron Pharmaceuticals from a sell rating to a strong sell rating and set a $368.84 target price on the stock. in a research note on Monday, May 15th. Piper Jaffray Companies increased their target price on shares of Regeneron Pharmaceuticals from $446.00 to $557.00 and gave the stock an overweight rating in a research note on Tuesday, June 20th. BMO Capital Markets increased their target price on shares of Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a hold rating in a research note on Monday, May 15th. Finally, Leerink Swann reissued an outperform rating and set a $493.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, June 13th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $496.35.

Shares of Regeneron Pharmaceuticals (REGN) opened at 437.74 on Monday. The firm has a market capitalization of $46.41 billion, a price-to-earnings ratio of 43.91 and a beta of 1.65. Regeneron Pharmaceuticals has a 52 week low of $325.35 and a 52 week high of $543.55. The firm has a 50-day moving average of $479.23 and a 200 day moving average of $445.02.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to analyst estimates of $1.36 billion. Regeneron Pharmaceuticals had a net margin of 22.05% and a return on equity of 25.58%. Regeneron Pharmaceuticals’s revenue was up 21.2% on a year-over-year basis. During the same period in the prior year, the firm earned $2.82 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Earns “Buy” Rating from Credit Suisse Group” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of United States & international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2017/09/14/regeneron-pharmaceuticals-inc-regn-earns-buy-rating-from-credit-suisse-group.html.

In related news, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Neil Stahl sold 8,306 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $532.55, for a total transaction of $4,423,360.30. Following the transaction, the executive vice president now directly owns 43,950 shares of the company’s stock, valued at approximately $23,405,572.50. The disclosure for this sale can be found here. Insiders sold 120,690 shares of company stock valued at $57,732,183 in the last quarter. Corporate insiders own 10.40% of the company’s stock.

Large investors have recently modified their holdings of the stock. Fieldpoint Private Securities LLC purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $130,000. Sterling Investment Advisors Ltd. grew its stake in Regeneron Pharmaceuticals by 11.2% during the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock valued at $137,000 after acquiring an additional 28 shares in the last quarter. FNY Managed Accounts LLC purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at approximately $140,000. FNY Partners Fund LP grew its stake in Regeneron Pharmaceuticals by 200.0% during the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 200 shares in the last quarter. Finally, Alpha Windward LLC grew its stake in Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 1 shares in the last quarter. 67.96% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.